Results 11 to 20 of about 381,135 (230)

Low molecular weight heparin in COVID-19: benefits and concerns

Frontiers in Pharmacology, 2023
Since its emergence, the COVID-19 pandemic had a dramatic impact on the public health worldwide and it scarred the medical, economical, and social determinants of health.
Adham Makarem, Adham Makarem, Rana Zareef, Joseph Abourjeili, Joseph E Nassar, Fadi Bitar, Fadi Bitar, Fadi Bitar, Mariam Arabi, Mariam Arabi, Mariam Arabi   +10 more
doaj   +1 more source

Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update

Cardiovascular Drugs and Therapy, 2021
Low molecular weight heparin (LMWH) is a glycosaminoglycan long known for its anticoagulant properties. In recent times, recent evidence has associated this drug with extra pleiotropic anticoagulant effects that have also proven useful in the management ...
A. Vitiello, F. Ferrara
semanticscholar   +1 more source

The Effect of Low Molecular Weight Heparins on Placentation: A Rat Model Study

Cumhuriyet Science Journal, 2022
Low molecular weight heparins (LMWHs) have been used for the treatment for recurrent pregnancy loss (RPL) for a long time. We aimed to investigate the efficacy of the LMWHs on angiogenesis and apoptosis during placentation.
Gülizar Özer, Çağlar Yıldız, Hatice Özer, Ali Çetin   +3 more
doaj   +1 more source

Low molecular weight heparins [PDF]

Intensive and Critical Care Nursing, 1996
A new class of anticoagulant with advantages over standard heparin were introduced in 1990. Collectively termed low molecular weight heparins, their role is increasing in the treatment and prophylaxis of thromboembolism.
openaire   +4 more sources

The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID‐19 Patients: A Retrospective Cohort Study

Clinical and Translational Science, 2020
On March 11, 2020, the World Health Organization declared its assessment of coronavirus disease 2019 (COVID‐19) as a global pandemic. However, specific anti‐severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) drugs are still under development ...
C. Shi, Cong Wang, Hanxiang Wang, Chao Yang, F. Cai, F. Zeng, F. Cheng, Yihui Liu, Tao Zhou, B. Deng, I. Vlodavsky, Jin-ping Li, Yu Zhang   +12 more
semanticscholar   +1 more source

Efficacy and safety of low-dose aspirin combined with low-molecular-weight heparin in treatment of preeclampsia: a meta-analysis and systematic review

Archives of Medical Science, 2021
Introduction The role of low-dose aspirin combined with low-molecular-weight heparin (LMWH) in the treatment of preeclampsia (PE) remains unclear. We aimed to assess the efficacy and safety of low-dose aspirin combined with LMWH in PE treatment, to ...
Chunfeng Wu, Liling Li, Jiarong Zhang, Yang Song   +3 more
doaj   +1 more source

Heparin-induced thrombocytopenia and acute colonic pseudo-obstruction after therapeutic anticoagulation in a very elderly patient with hip fracture: a case report

BMC Musculoskeletal Disorders, 2020
Background Hip fractures have become a severe public health problem, especially in very elderly patients. Most of them are treated with low molecular weight heparin as prophylaxis or treatment of venous thromboembolism.
Yijun Liu, Hao Lu, Hailin Xu, Zhongguo Fu, Dianying Zhang, Baoguo Jiang   +5 more
doaj   +1 more source

Present and future of low molecular weight heparin prophylaxis [PDF]

, 1999
Peer ...
Kakkar, V. V.
core   +2 more sources

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Journal of Clinical Oncology, 2018
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients.
A. Young, A. Marshall, Jenny Thirlwall, O. Chapman, A. Lokare, C. Hill, Danielle Hale, J. Dunn, G. Lyman, Charles E. Hutchinson, P. Maccallum, Ajay Kakkar, F. Hobbs, S. Petrou, J. Dale, C. Poole, A. Maraveyas, M. Levine   +17 more
semanticscholar   +1 more source

The potential for circular dichroism as an additional facile and sensitive method of monitoring low-molecular-weight heparins and heparinoids [PDF]

, 2009
The ultraviolet circular dichroism (CD) spectra of commercial low-molecular-weight heparins, heparinoids and other anticoagulant preparations have been recorded between 180 and 260 nm.
Fernig, David G., Guimond, Scott E., Holman, Joseph, Lauder, Robert M., Rudd, Timothy R., Skidmore, Mark A., Turnbull, Jeremy E., Yates, Edwin A.   +7 more
core   +1 more source